How supplied information for XELJANZ/XELJANZ XR is shown in Table 22.
| Bottle Size (number of tablets) | NDC Number | |
|---|---|---|
XELJANZ | 60 | NDC 0069-1001-01 |
XELJANZ | 60 | NDC 0069-1002-01 |
XELJANZ XR | 30 | NDC 0069-0501-30 |
XELJANZ XR | 30 | NDC 0069-0502-30 |
How supplied information for XELJANZ Oral Solution is shown in Table 23.
| Bottle Fill (volume mL) | NDC Number | |
|---|---|---|
XELJANZ Oral Solution | 240 mL | NDC 0069-1029-02 |
XELJANZ/XELJANZ XR
Store XELJANZ/XELJANZ XR at 20°C to 25°C (68°F to 77°F). [See USP Controlled Room Temperature].
Do not repackage.
XELJANZ Oral Solution
XELJANZ 1 mg/ mL oral solution is a clear, colorless solution that contains 1 mg of tofacitinib. It is packaged in HDPE bottles as follows:
Each bottle is packaged with one press-in bottle adapter and one 5 mL oral dosing syringe with 3.2 mL, 4 mL, and 5 mL gradations. The press-in bottle adapter and oral dosing syringe are not made with natural rubber latex.
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F). [See USP Controlled Room Temperature].
Store in the original bottle and carton to protect from light.
Use contents of bottle within 60 days of opening.
Discard remaining oral solution after 60 days.
How supplied information for XELJANZ/XELJANZ XR is shown in Table 22.
| Bottle Size (number of tablets) | NDC Number | |
|---|---|---|
XELJANZ | 60 | NDC 0069-1001-01 |
XELJANZ | 60 | NDC 0069-1002-01 |
XELJANZ XR | 30 | NDC 0069-0501-30 |
XELJANZ XR | 30 | NDC 0069-0502-30 |
How supplied information for XELJANZ Oral Solution is shown in Table 23.
| Bottle Fill (volume mL) | NDC Number | |
|---|---|---|
XELJANZ Oral Solution | 240 mL | NDC 0069-1029-02 |
XELJANZ/XELJANZ XR
Store XELJANZ/XELJANZ XR at 20°C to 25°C (68°F to 77°F). [See USP Controlled Room Temperature].
Do not repackage.
XELJANZ Oral Solution
XELJANZ 1 mg/ mL oral solution is a clear, colorless solution that contains 1 mg of tofacitinib. It is packaged in HDPE bottles as follows:
Each bottle is packaged with one press-in bottle adapter and one 5 mL oral dosing syringe with 3.2 mL, 4 mL, and 5 mL gradations. The press-in bottle adapter and oral dosing syringe are not made with natural rubber latex.
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F). [See USP Controlled Room Temperature].
Store in the original bottle and carton to protect from light.
Use contents of bottle within 60 days of opening.
Discard remaining oral solution after 60 days.
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.